Search

Your search keyword '"Harbo T."' showing total 4 results
Start Over Author "Harbo T." Publisher den alm danske laegerforening
4 results on '"Harbo T."'

1. [ECT in autoimmune encephalitis].

Author

Waaler HO and Harbo T

Subjects
Adult, Encephalitis, Humans, Male, Anti-N-Methyl-D-Aspartate Receptor Encephalitis complications, Anti-N-Methyl-D-Aspartate Receptor Encephalitis diagnosis, Anti-N-Methyl-D-Aspartate Receptor Encephalitis drug therapy, Catatonia drug therapy, Electroconvulsive Therapy, Hashimoto Disease complications, Hashimoto Disease drug therapy
Abstract

In this case report, a 27-year-old male presented at a department of neurology with postherpetic anti-N-methyl-d-aspartate (NMDA) receptor autoimmune encephalitis. The patient was psychotic and exhibited symptoms of akinetic and excited catatonia. He was mechanical restrained for a total of 46 days due to violent behaviour. He was treated with olanzapine and lorazepam up to 15 mg/day without effect on catatonic and behavioural symptoms. ECT was initiated, and the patient received a total of 16 treatments. He responded well to the treatment, and the violent behaviour resolved completely after the first treatment. ECT should be considered for catatonia in anti-NMDA-receptor autoimmune encephalitis.

Published
2021

2. [Chronic inflammatory demyelinating polyneuropathy].

Author

Markvardsen LK, Harbo T, Holbech JV, Tankisi H, Christiansen I, Olsen NK, Jakobsen J, Sindrup SH, and Andersen H

Subjects
Humans, Peripheral Nerves, Sensation Disorders, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating diagnosis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating drug therapy
Abstract

In this review, we discuss chronic inflammatory demyelinating polyneuropathy (CIDP), which is a disease with proximal and distal weakness and sensory disturbances resulting in impaired daily activity. The diagnosis is based on the clinical presentation and electrophysiology demonstrating demyelination in the peripheral nerves. CIDP can be successfully treated with immunoglobulin, glucocorticoids or plasma exchange, and during the latest decade, immunoglobulin has been administered subcutaneously improving patients' flexibility and autonomy. By time, 30% of the patients will remit, and maintenance treatment will no longer be necessary.

Published
2019

3. [Valproate can induce reversible encephalopathy].

Author

Prakash S, Harbo T, and Christensen J

Subjects
Aged, Anticonvulsants therapeutic use, Brain Diseases diagnosis, Epilepsy drug therapy, Female, Humans, Magnetic Resonance Imaging, Neurotoxicity Syndromes diagnosis, Valproic Acid therapeutic use, Anticonvulsants adverse effects, Brain Diseases etiology, Neurotoxicity Syndromes etiology, Valproic Acid adverse effects
Abstract

Valproate (VPA) is a widely used antiepileptic drug – also in the elderly. A female patient was diagnosed with epilepsy at the age 60 of years and treated with VPA for 16 years before developing tremor, rigidity, cognitive impairment and descending consciousness progressing to coma. After discontinuation of VPA she regained full consciousness, could talk and feed herself. The extrapyramidal and cognitive symptoms completely subsided during the following months. VPA-induced encephalopathy is an uncommon but serious adverse effect that should be considered in patients with cognitive decline during VPA treatment.

Published
2015

4. [Valproate can induce reversible encephalopathy].

Author

Prakash S, Harbo T, and Christensen J

Subjects
Aged, Anticonvulsants therapeutic use, Brain Diseases diagnosis, Epilepsy drug therapy, Female, Humans, Magnetic Resonance Imaging, Neurotoxicity Syndromes diagnosis, Valproic Acid therapeutic use, Anticonvulsants adverse effects, Brain Diseases chemically induced, Neurotoxicity Syndromes etiology, Valproic Acid adverse effects
Abstract

Valproate (VPA) is a widely used antiepileptic drug - also in the elderly. A female patient was diagnosed with epilepsy at the age of 60 years and treated with VPA for 16 years before developing tremor, rigidity, cognitive impairment and descending consciousness progressing to coma. After discontinuation of VPA she regained full consciousness, could talk and feed herself. The extrapyramidal and cognitive symptoms completely subsided during the following months. VPA-induced encephalopathy is an uncommon but serious adverse effect that should be considered in patients with cognitive decline during VPA treatment.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results